View larger
Interleukin-12 p35 Human Recombinant ( IL 12 p35 Human )
DescriptionInterleukin-12 p35 His Human ? Recombinant produced in E.Coli is single, a non-glycosylated, polypeptide chain containing 197 amino acids fragment (57-253) with an amino-terminal hexahistidine tag. The IL-12 p35 His is purified by
Data sheet
| Formulation | Interleukin-12 p35 His-Tag is supplied in 1xPBS and 50% glycerol. |
| Purity | Greater than 95.0% as determined by SDS-PAGE. |
| Description | Interleukin-12 p35 His Human Recombinant produced in E.Coli is single, a non-glycosylated, polypeptide chain containing 197 amino acids fragment (57-253) with an amino-terminal hexahistidine tag. The IL-12 p35 His is purified by proprietary chromatographic techniques. |
| Protein Background | Active IL-12 is a p70 disulphide-linked dimer composed of p35 and p40 subunits. The protein is a pleiotropic cytokine produced primarily by antigen presenting cells and has multiple effects on T lymphocytes and natural killer cells in terms of stimulating cytotoxicity, proliferation, production of other cytokines and Th1 subset differentiation. |
| Expression host | Escherichia Coli. |
| Synonyms | NKSF1, CTL maturation factor (TCMF), Cytotoxic lymphocyte maturation factor 35 kDa subunit (CLMF p35), TSF, Edodekin-alpha, IL-12 p35, IL-12A, IL-12 subunit p35, NK cell stimulatory factor chain 1, SGT2, FLJ39002. |
| Reagent Appearance | Sterile Filtered clear solution. |
| Stability | Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. Please avoid freeze thaw cycles. |
| Protein formulation | Contains thimerosal (0.005%) and sodium azide (0.1%) as preservative. Although the amounts are very small, appropriate care must be taken when handling this product. |
| Protein concentration | Serological studies of influenza B virus, immunogen for antibody production. |
| Immunological Activity | Thimerosal and beta propiolactone treatmentThis product has been treated in a manner consistent with methods of inactivation. Generally accepted good laboratory practices appropriate to microbiological/viral safe handling practices and techniques are required at work. |
| Reference | Tested with anti-influenza B monoclonal antibodies in ELISA. |